Postmarketing Surveillance Study With MOBEC®

The aim of the study is to investigate

* the indication for MOBEC in a dose of 15 mg per day * the treatments patients were receiving before switching to 15 mg MOBEC * how treatment with 15 mg is assessed compared with previous treatment * how effective and safe treatment with 15 mg MOBEC is considered

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

An indication for a treatment with 15 mg MOBEC of at least four weeks

the symptomatic short-term treatment of osteoarthritis
the symptomatic long-term treatment of rheumatoid arthritis (chronic polyarthritis); restriction: the recommended dose for long-term treatment of elderly patients is 7.5 mg)
the symptomatic treatment of ankylosing spondylitis

Exclusion criteria

Treatment with MOBEC prior to the start of the study
Patients with any of the general or specific contraindications of MOBEC

Treatment and study plan

MOBEC

Drug

Primary outcomes

Nature and incidence of adverse drug reactions (ADR)

Time frame: up to week 8
Assessment of efficacy by physician on a 5-point scale

Time frame: up to week 8
Assessment of tolerability by physician on a 5-point scale

Time frame: up to week 8

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

COX-2 Postmarketing Surveillance Study With MOBEC® 15 mg Tablets

Important dates

Study start: 2001
Primary completion: 2001
First posted: Jul 8, 2014
Registry last updated: Jul 9, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed